Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
- PMID: 35573354
- PMCID: PMC9091654
- DOI: 10.3389/fpsyt.2022.868751
Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
Abstract
Social dysfunction is one of the most debilitating aspects of schizophrenia. Treatment of this complex phenomenon, constituted by negative, cognitive, and affective symptoms, has been difficult with the available pharmacological agents, hence it represents an unmet medical need. Cariprazine, a novel, third-generation antipsychotic with a unique mechanism of action has been proven to sufficiently alleviate negative, cognitive, and affective symptoms of schizophrenia. These characteristics make this compound a valid candidate for addressing social dysfunction too. In this perspective, we argue that cariprazine can be viewed as a "socializing drug" that has the ability to improve the patient's functionality and ultimately their quality of life. Data from animal research, clinical trials, an observational study, and patient cases are provided.
Keywords: D3 receptors; antipsychotic; cariprazine; schizophrenia; social dysfunction.
Copyright © 2022 Morozov, Bekker and Bykov.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy.Cureus. 2023 May 21;15(5):e39309. doi: 10.7759/cureus.39309. eCollection 2023 May. Cureus. 2023. PMID: 37378203 Free PMC article. Review.
-
Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects.Int Clin Psychopharmacol. 2023 Sep 1;38(5):361-366. doi: 10.1097/YIC.0000000000000469. Epub 2023 Jun 12. Int Clin Psychopharmacol. 2023. PMID: 37351582
-
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.Int J Neuropsychopharmacol. 2017 Oct 1;20(10):788-796. doi: 10.1093/ijnp/pyx038. Int J Neuropsychopharmacol. 2017. PMID: 28531264 Free PMC article.
-
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.Adv Ther. 2021 Jul;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5. Epub 2021 Jun 6. Adv Ther. 2021. PMID: 34091867 Free PMC article. Review.
-
The role of dopamine D3 receptors in the mechanism of action of cariprazine.CNS Spectr. 2020 Jun;25(3):343-351. doi: 10.1017/S109285291900083X. Epub 2019 Apr 23. CNS Spectr. 2020. PMID: 31010452 Review.
Cited by
-
Successful switching from risperidone to cariprazine in a schizophrenic patient with pronounced functional deficit. Case report.Front Psychiatry. 2023 Mar 20;14:1155395. doi: 10.3389/fpsyt.2023.1155395. eCollection 2023. Front Psychiatry. 2023. PMID: 37020736 Free PMC article.
-
Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series.Front Psychiatry. 2022 Aug 1;13:878889. doi: 10.3389/fpsyt.2022.878889. eCollection 2022. Front Psychiatry. 2022. PMID: 35978843 Free PMC article.
References
-
- WHO . WHO | Schizophrenia. Schizophrenia. 2018.
-
- Bleuler E. Dementia Praecox or the Group of Schizophrenias. Translated by Joseph Zinkin. Int Univ Press; (1950)
LinkOut - more resources
Full Text Sources
